Edwards Lifesciences Corp

$71.15
(as of Jan 13, 3:59 PM EST)

Stock Market Guides is not a financial advisor. Our content is strictly educational and should not be considered financial advice.

Ticker Information for Edwards Lifesciences Corp

Stock Price
$71.15
Ticker Symbol
EW
Exchange
NYSE

Industry Information for Edwards Lifesciences Corp

Sector
Healthcare
Industry
Medical Devices

Company Description for Edwards Lifesciences Corp

Country
USA
Full Time Employees
19,800

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names. The company also provides surgical structural heart solutions, such as aortic surgical valve under the INSPIRIS name; INSPIRIS RESILLA aortic valve, which offers RESILIA tissue and VFit technology; KONECT RESILIA, a pre-assembled tissue valves conduit for complex combined procedures; and MITRIS RESILIA valve. In addition, it offers critical care solutions, including hemodynamic monitoring systems to measure a patient's heart function and fluid status in surgical and intensive care settings under the FloTrac, Acumen IQ sensors, ClearSight, Acumen IQ cuffs, and ForeSight names; HemoSphere, a monitoring platform that displays physiological information; and Acumen Hypotension Prediction Index software that alerts clinicians in advance of a patient developing dangerously low blood pressure. The company distributes its products through a direct sales force and independent distributors. Edwards Lifesciences Corporation was founded in 1958 and is headquartered in Irvine, California.

Fundamentals for Edwards Lifesciences Corp

Market Capitalization
$43,303,120,896
EBITDA
$2,052,400,000
Dividends per Share
P/E Ratio
28.32
Forward P/E Ratio
30.3
Earnings per Share
$2.51
Earnings per Share Estimate Next Year
$2.45
Profit Margin
65.86%
Shares Outstanding
589,800,000
Percent Owned by Insiders
0.91%
Percent Owned by Institutions
86.14%
52-Week High
$96.12
52-Week Low
$58.93

Technical Indicators for Edwards Lifesciences Corp

50-Day Moving Average
$71.17
200-Day Moving Average
$77.17
RSI
41.31
1.77

Analyst Ratings for Edwards Lifesciences Corp

Strong Buy
9
Buy
5
Hold
19
Sell
0
Strong Sell
0

News About Edwards Lifesciences Corp

Oct 25, 2024, 4:23 PM EST
Edwards Lifesciences stock fell Friday after the company said its TAVR segment will face numerous challenges in the fourth quarter. See more.
Oct 21, 2024, 9:16 AM EST
In its upcoming report, Edwards Lifesciences (EW) is predicted by Wall Street analysts to post quarterly earnings of $0.67 per share, reflecting an increase of 13.6% compared to the same period last year. See more.
Oct 18, 2024, 7:00 AM EST
Many investors define successful investing as beating the market average over the long term. See more.
Oct 17, 2024, 10:01 AM EST
Wall Street expects a year-over-year decline in earnings on higher revenues when DexCom (DXCM) reports results for the quarter ended September 2024. See more.
Oct 17, 2024, 7:05 AM EST
IRVINE, Calif., October 17, 2024--(BUSINESS WIRE)--Edwards Lifesciences (NYSE: EW) plans to announce its operating results for the quarter ended September 30, 2024 after the market closes on Thursday, October 24, 2024, and will host a conference call at 5:30 p.m. See more.